Top Markets
Coin of the day
Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

CTXR
주식 순위 #33050
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm... Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
주가
$0.5625
시가총액
$6.29M
변동 (1일)
-25.56%
변동 (1년)
-57.71%
국가
US
거래 Citius Pharmaceuticals, Inc. (CTXR)

카테고리

Citius Pharmaceuticals, Inc. (CTXR)의 주가 이력
최고 종가: $0.69 (2026-08-01 기준)

최저 종가: $374.99 (2014-10-01 기준)
Citius Pharmaceuticals, Inc.의 주가 이력 (2014 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) -13.63%
2025 -66.66%
2024 -83.96%
2023 -24.36%
2022 -35.96%
2021 48.68%
2020 66.19%
2019 -38.70%
2018 -76.18%
2017 -33.16%
2016 -74.07%
2015 50.02%
2014 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$511.97 30.34%
US
$984.83 50.62%
NL
$736.38 7.15%
CH
$1.07K -6.40%
KR
$255.62 13.43%
BE